董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marc Oczachowski | 男 | Chief Executive Officer of EDAP TMS S.A. and Chairman of the Board of Director,President of EDAP TMS France SAS and EDAP Technomed, Inc. | 50 | 未披露 | 未持股 | 2020-04-16 |
| Philippe Chauveau | 男 | Director | 84 | 未披露 | 未持股 | 2020-04-16 |
| Pierre Beysson | 男 | Director | 78 | 未披露 | 未持股 | 2020-04-16 |
| Argil Wheelock | 男 | Director | 72 | 未披露 | 未持股 | 2020-04-16 |
| Rob Michiels | 男 | Director | 70 | 未披露 | 未持股 | 2020-04-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Francois Dietsch | 男 | Chief Financial Officer of EDAP TMS S.A. | 44 | 未披露 | 未持股 | 2020-04-16 |
| Marc Oczachowski | 男 | Chief Executive Officer of EDAP TMS S.A. and Chairman of the Board of Director,President of EDAP TMS France SAS and EDAP Technomed, Inc. | 50 | 未披露 | 未持股 | 2020-04-16 |
董事简历
中英对照 | 中文 | 英文- Marc Oczachowski
-
Marc Oczachowski，1997年5月，他加入公司，担任法国里昂地区销售经理；2001年3月至2004年1月，他在EDAP Technomed Malaysia担任总经理；2004年11月，他被任命为EDAP TMS首席运营官；2007年3月31日，他成为公司首席行政官；2012年7月1日，他被重新分配到特克萨斯州奥斯汀，管理美国地区运营。他曾在Sodem Systems（整形手术工具制造商）担任地区销售经理。他是法国里昂商学院业毕业生。
Marc Oczachowski joined the Company in May 1997 as Area Sales Manager, based in Lyon, France. From March 2001 to January 2004 he held management positions as General Manager of EDAP Technomed Malaysia. He was appointed Chief Operating Officer of EDAP TMS in November 2004 and became Chief Executive Officer of the Company on March 31 2007. From July 2012 to July 2017 he relocated to Austin, Texas to manage EDAP’s U.S. operations. On March 25 2020 he was appointed Chairman of the Board of Directors following Philippe Chauveau’s decision to step down from this position. Previously he worked for Sodem Systems, which manufactures orthopedic power tools, as Area Sales Manager. He is a graduate of Institut Commercial de Lyon, France. - Marc Oczachowski，1997年5月，他加入公司，担任法国里昂地区销售经理；2001年3月至2004年1月，他在EDAP Technomed Malaysia担任总经理；2004年11月，他被任命为EDAP TMS首席运营官；2007年3月31日，他成为公司首席行政官；2012年7月1日，他被重新分配到特克萨斯州奥斯汀，管理美国地区运营。他曾在Sodem Systems（整形手术工具制造商）担任地区销售经理。他是法国里昂商学院业毕业生。
- Marc Oczachowski joined the Company in May 1997 as Area Sales Manager, based in Lyon, France. From March 2001 to January 2004 he held management positions as General Manager of EDAP Technomed Malaysia. He was appointed Chief Operating Officer of EDAP TMS in November 2004 and became Chief Executive Officer of the Company on March 31 2007. From July 2012 to July 2017 he relocated to Austin, Texas to manage EDAP’s U.S. operations. On March 25 2020 he was appointed Chairman of the Board of Directors following Philippe Chauveau’s decision to step down from this position. Previously he worked for Sodem Systems, which manufactures orthopedic power tools, as Area Sales Manager. He is a graduate of Institut Commercial de Lyon, France.
- Philippe Chauveau
-
Philippe Chauveau，1997年，他被任命为EDAP TMS S.A.董事会主席；2002年，双层董事结构被单层董事结构取代，他担任主席兼首席行政官直到2004年他继续担任首席行政官；2000年至2007年，他担任Scynexis Inc（位于美国的创新药物研发公司，与全球主要制药企业合伙，由私人控股企业提供基金支持）创立主席。他是AT&T Bell Labs 研发部副总裁，在ITT和Procter & Gamble在市场营销上扮演着越来越重要的作用之前，他是Apple Computer Europe主席。他获有都柏林圣三一学院荣誉文理科学士学位。
Philippe Chauveau was named chairman of EDAP TMS S.A.'s Supervisory Board in 1997 and resigned from his position of Chairman of the Board on March 25 2020 when Marc Oczachowski was appointed Chairman. In 2002 the Company’s two-tiered board structure was replaced by a single Board of Directors with Philippe Chauveau serving as Chairman and CEO until 2004 when he was succeeded as CEO. From 2000 to 2007 Philippe Chauveau served as founding Chairman of the Board of Scynexis Inc., funded by private equity, which is an innovative drug discovery company based in the United States. He was Vice-President of research and development at AT&T Bell Labs and has also served as Chairman of Apple Computer Europe, preceded by increasing marketing roles in ITT and in Procter & Gamble. He has an Honours Degree from Trinity College Dublin with a B.A. and a Bsc. - Philippe Chauveau，1997年，他被任命为EDAP TMS S.A.董事会主席；2002年，双层董事结构被单层董事结构取代，他担任主席兼首席行政官直到2004年他继续担任首席行政官；2000年至2007年，他担任Scynexis Inc（位于美国的创新药物研发公司，与全球主要制药企业合伙，由私人控股企业提供基金支持）创立主席。他是AT&T Bell Labs 研发部副总裁，在ITT和Procter & Gamble在市场营销上扮演着越来越重要的作用之前，他是Apple Computer Europe主席。他获有都柏林圣三一学院荣誉文理科学士学位。
- Philippe Chauveau was named chairman of EDAP TMS S.A.'s Supervisory Board in 1997 and resigned from his position of Chairman of the Board on March 25 2020 when Marc Oczachowski was appointed Chairman. In 2002 the Company’s two-tiered board structure was replaced by a single Board of Directors with Philippe Chauveau serving as Chairman and CEO until 2004 when he was succeeded as CEO. From 2000 to 2007 Philippe Chauveau served as founding Chairman of the Board of Scynexis Inc., funded by private equity, which is an innovative drug discovery company based in the United States. He was Vice-President of research and development at AT&T Bell Labs and has also served as Chairman of Apple Computer Europe, preceded by increasing marketing roles in ITT and in Procter & Gamble. He has an Honours Degree from Trinity College Dublin with a B.A. and a Bsc.
- Pierre Beysson
-
Pierre Beysson，2002年9月，他被任命为董事会成员。之后，他成为Compagnie des Wagons-Lits （CWL，Accor这个法国跨国酒店及商业服务集团的车载列车服务部）首席财务官，他在Accor Group相关公司董事会任职。他是会计师。在CWL工作之前，他在Nixdorf Computers, Trane （冷气工程）， AM International （办公设备）以及FMC （石油设备）担任高级财务职务。他是注册公共会计师，受到专业训练，有着审计经验。他获有哈佛商学院工商管理硕士学位。
Pierre Beysson was appointed as a member of the Board of Directors in September 2002. Pierre Beysson was then the Chief Financial Officer of Compagnie des Wagons-Lits "CWL", the on-board train service division of Accor, a French multinational Hotel and Business Services Group. In this capacity, he sat on a number of boards of companies related to the Accor Group. Before his assignment at CWL, Pierre Beysson held a number of senior financial positions with Nixdorf Computers, Trane Air Conditioning, AM International Office Equipment and FMC (Petroleum Equipment). Pierre Beysson was trained as a CPA, has auditing experience and holds an MBA from Harvard Business School. - Pierre Beysson，2002年9月，他被任命为董事会成员。之后，他成为Compagnie des Wagons-Lits （CWL，Accor这个法国跨国酒店及商业服务集团的车载列车服务部）首席财务官，他在Accor Group相关公司董事会任职。他是会计师。在CWL工作之前，他在Nixdorf Computers, Trane （冷气工程）， AM International （办公设备）以及FMC （石油设备）担任高级财务职务。他是注册公共会计师，受到专业训练，有着审计经验。他获有哈佛商学院工商管理硕士学位。
- Pierre Beysson was appointed as a member of the Board of Directors in September 2002. Pierre Beysson was then the Chief Financial Officer of Compagnie des Wagons-Lits "CWL", the on-board train service division of Accor, a French multinational Hotel and Business Services Group. In this capacity, he sat on a number of boards of companies related to the Accor Group. Before his assignment at CWL, Pierre Beysson held a number of senior financial positions with Nixdorf Computers, Trane Air Conditioning, AM International Office Equipment and FMC (Petroleum Equipment). Pierre Beysson was trained as a CPA, has auditing experience and holds an MBA from Harvard Business School.
- Argil Wheelock
-
Argil Wheelock，2009年6月，他被选为公司董事会成员。他是美国注册泌尿科医师，目前是Erlanger Medical Center（位于田纳西州查塔努加的三级护理教学医院）首席泌尿科医师。他是HealthTronics（私人控股公司）首席医药顾问，HealthTronics是一家领先的泌尿系统疾病的服务和产品供应商。1996年至2005年，他是HealthTronics（纽约证券交易所上市公司）创始人，担任总裁兼首席行政官。他成功建立了一个为引进新医疗设备的记录以及引导美国食品药物管理局的批准过程。他为患者和泌尿疾病实践经济价值带来了临床利益，使得他在美国泌尿疾病界广为人知。他毕业于田纳西大学医学院，在纽约城的西乃山医院完成了他的泌尿疾病培训。
Argil Wheelock was elected as a member of the Company's Board of Directors in June 2009. Dr. Wheelock, a U.S. board certified urologist, is currently Senior Physician at the University of Tennessee Department of Urology at Erlanger Medical Center, a tertiary care and teaching hospital in Chattanooga, Tennessee. He is Chief Medical Advisor to HealthTronics Inc., a privately held company. HealthTronics is a leading U.S. provider of urological services and products. From 1996 to 2005 Dr. Wheelock served as Chairman and CEO of HealthTronics, a publicly traded NASDAQ company where he was a founder. He has built a successful track record introducing new medical devices to the U.S. and navigating the FDA approval process. He is widely known among the U.S. urological community. Dr. Wheelock graduated from the University of Tennessee College of Medicine and completed urological training at Mount Sinai Hospital in New York City. - Argil Wheelock，2009年6月，他被选为公司董事会成员。他是美国注册泌尿科医师，目前是Erlanger Medical Center（位于田纳西州查塔努加的三级护理教学医院）首席泌尿科医师。他是HealthTronics（私人控股公司）首席医药顾问，HealthTronics是一家领先的泌尿系统疾病的服务和产品供应商。1996年至2005年，他是HealthTronics（纽约证券交易所上市公司）创始人，担任总裁兼首席行政官。他成功建立了一个为引进新医疗设备的记录以及引导美国食品药物管理局的批准过程。他为患者和泌尿疾病实践经济价值带来了临床利益，使得他在美国泌尿疾病界广为人知。他毕业于田纳西大学医学院，在纽约城的西乃山医院完成了他的泌尿疾病培训。
- Argil Wheelock was elected as a member of the Company's Board of Directors in June 2009. Dr. Wheelock, a U.S. board certified urologist, is currently Senior Physician at the University of Tennessee Department of Urology at Erlanger Medical Center, a tertiary care and teaching hospital in Chattanooga, Tennessee. He is Chief Medical Advisor to HealthTronics Inc., a privately held company. HealthTronics is a leading U.S. provider of urological services and products. From 1996 to 2005 Dr. Wheelock served as Chairman and CEO of HealthTronics, a publicly traded NASDAQ company where he was a founder. He has built a successful track record introducing new medical devices to the U.S. and navigating the FDA approval process. He is widely known among the U.S. urological community. Dr. Wheelock graduated from the University of Tennessee College of Medicine and completed urological training at Mount Sinai Hospital in New York City.
- Rob Michiels
-
Rob Michiels，2009年7月，他被选为董事会成员。他在医疗设备行业有着30年的经验。目前，他是CardiAQ Valve Technologies（发展经导管二尖瓣植入的风险投资创业公司）首席行政官。他还曾是CoreValve首席运营官，InterVentional Technologies的总裁兼首席运营官。他使用对高强度聚焦超声具有很强协同效应的创新技术促进心血管创业公司以及完善的市场领导公司的发展。他是CardiAQ Valve Technologies以及Embolization Prevention Technologies这两个私人控股公司的董事。他还是CONSILIUM（在识别、资金和温室效应启动技术方面活跃的医疗设备市场研究公司）创立合伙人。精通英语、法语以及荷兰语。他获有比利时安特卫普大学经济学学士学位以及印第安纳大学工商管理硕士学位。
Rob Michiels was elected as a member of the Company's Board of Directors in July 2009. He is a 40-year U.S. veteran of the medical device industry. He most recently serves as Chief Executive Officer CEO of CardiAQ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation which was acquired by Edwards Lifesciences during the second half of 2015. He previously served as Chief Operating Officer COO of CoreValve acquired by Medtronic; and as President and COO of InterVentional Technologies (acquired by Boston Scientific). He helped drive both companies from cardiovascular start-ups to established market leaders, using new and innovative technologies which have strong synergies to the HIFU story. Rob Michiels is a director of Conveyor Ltd and FEops NV, all privately held companies developing cutting edge cardio-vascular less-invasive Technologies. Rob Michiels is a founding partner of CONSILIUM, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch languages, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Master’s in business administration (MBA) from Indiana University. - Rob Michiels，2009年7月，他被选为董事会成员。他在医疗设备行业有着30年的经验。目前，他是CardiAQ Valve Technologies（发展经导管二尖瓣植入的风险投资创业公司）首席行政官。他还曾是CoreValve首席运营官，InterVentional Technologies的总裁兼首席运营官。他使用对高强度聚焦超声具有很强协同效应的创新技术促进心血管创业公司以及完善的市场领导公司的发展。他是CardiAQ Valve Technologies以及Embolization Prevention Technologies这两个私人控股公司的董事。他还是CONSILIUM（在识别、资金和温室效应启动技术方面活跃的医疗设备市场研究公司）创立合伙人。精通英语、法语以及荷兰语。他获有比利时安特卫普大学经济学学士学位以及印第安纳大学工商管理硕士学位。
- Rob Michiels was elected as a member of the Company's Board of Directors in July 2009. He is a 40-year U.S. veteran of the medical device industry. He most recently serves as Chief Executive Officer CEO of CardiAQ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation which was acquired by Edwards Lifesciences during the second half of 2015. He previously served as Chief Operating Officer COO of CoreValve acquired by Medtronic; and as President and COO of InterVentional Technologies (acquired by Boston Scientific). He helped drive both companies from cardiovascular start-ups to established market leaders, using new and innovative technologies which have strong synergies to the HIFU story. Rob Michiels is a director of Conveyor Ltd and FEops NV, all privately held companies developing cutting edge cardio-vascular less-invasive Technologies. Rob Michiels is a founding partner of CONSILIUM, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch languages, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Master’s in business administration (MBA) from Indiana University.
高管简历
中英对照 | 中文 | 英文- Francois Dietsch
Francois Dietsch于2005年加入EDAP，担任内部审计和合并经理，领导萨班斯-奥克斯利法案（Sarbanes-Oxley）合规内部控制的实施，合并公司子公司的财务报表，并按照美国公认会计原则编制财务报表，包括EDAP公司的20-F表年度报告。2012年，他被提拔为EDAP公司的法国子公司的集团财务控制经理和财务经理，在那里，除了他之前的职责之外，他管理子公司层面的会计师事务所关系，是公司与其外部审计师之间的主要联络人。他还在EDAP France管理财务部门。他于2015年7月14日被任命为公司首席财务官。加入EDAP公司之前，他曾担任Valeo公司（汽车行业领先的全球零部件和系统供应商）的财务职务。他持有University of Paris Dauphine的管理和企业财务硕士学位。
Francois Dietsch joined EDAP in 2005 as Internal Audit and Consolidation Manager, leading the implementation of internal controls for Sarbanes-Oxley Compliance, consolidation of financial statements from the Company's subsidiaries and preparation of financial statements in accordance with U.S. GAAP, including EDAP's Annual Report on Form 20-F. In 2012 he was promoted to Group Financial Control Manager and Finance Manager of EDAP's French subsidiary where, in addition to his previous responsibilities, he managed accounting firm relationships at the subsidiary level and was the primary liaison between the Company and its external auditors. He also managed the Finance department at EDAP France. He was appointed Chief Financial Officer of the Company on July 14 2015. Prior to joining EDAP he held finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds Master's Degrees in Management and Corporate Finance from University of Paris Dauphine.- Francois Dietsch于2005年加入EDAP，担任内部审计和合并经理，领导萨班斯-奥克斯利法案（Sarbanes-Oxley）合规内部控制的实施，合并公司子公司的财务报表，并按照美国公认会计原则编制财务报表，包括EDAP公司的20-F表年度报告。2012年，他被提拔为EDAP公司的法国子公司的集团财务控制经理和财务经理，在那里，除了他之前的职责之外，他管理子公司层面的会计师事务所关系，是公司与其外部审计师之间的主要联络人。他还在EDAP France管理财务部门。他于2015年7月14日被任命为公司首席财务官。加入EDAP公司之前，他曾担任Valeo公司（汽车行业领先的全球零部件和系统供应商）的财务职务。他持有University of Paris Dauphine的管理和企业财务硕士学位。
- Francois Dietsch joined EDAP in 2005 as Internal Audit and Consolidation Manager, leading the implementation of internal controls for Sarbanes-Oxley Compliance, consolidation of financial statements from the Company's subsidiaries and preparation of financial statements in accordance with U.S. GAAP, including EDAP's Annual Report on Form 20-F. In 2012 he was promoted to Group Financial Control Manager and Finance Manager of EDAP's French subsidiary where, in addition to his previous responsibilities, he managed accounting firm relationships at the subsidiary level and was the primary liaison between the Company and its external auditors. He also managed the Finance department at EDAP France. He was appointed Chief Financial Officer of the Company on July 14 2015. Prior to joining EDAP he held finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds Master's Degrees in Management and Corporate Finance from University of Paris Dauphine.
- Marc Oczachowski
Marc Oczachowski，1997年5月，他加入公司，担任法国里昂地区销售经理；2001年3月至2004年1月，他在EDAP Technomed Malaysia担任总经理；2004年11月，他被任命为EDAP TMS首席运营官；2007年3月31日，他成为公司首席行政官；2012年7月1日，他被重新分配到特克萨斯州奥斯汀，管理美国地区运营。他曾在Sodem Systems（整形手术工具制造商）担任地区销售经理。他是法国里昂商学院业毕业生。
Marc Oczachowski joined the Company in May 1997 as Area Sales Manager, based in Lyon, France. From March 2001 to January 2004 he held management positions as General Manager of EDAP Technomed Malaysia. He was appointed Chief Operating Officer of EDAP TMS in November 2004 and became Chief Executive Officer of the Company on March 31 2007. From July 2012 to July 2017 he relocated to Austin, Texas to manage EDAP’s U.S. operations. On March 25 2020 he was appointed Chairman of the Board of Directors following Philippe Chauveau’s decision to step down from this position. Previously he worked for Sodem Systems, which manufactures orthopedic power tools, as Area Sales Manager. He is a graduate of Institut Commercial de Lyon, France.- Marc Oczachowski，1997年5月，他加入公司，担任法国里昂地区销售经理；2001年3月至2004年1月，他在EDAP Technomed Malaysia担任总经理；2004年11月，他被任命为EDAP TMS首席运营官；2007年3月31日，他成为公司首席行政官；2012年7月1日，他被重新分配到特克萨斯州奥斯汀，管理美国地区运营。他曾在Sodem Systems（整形手术工具制造商）担任地区销售经理。他是法国里昂商学院业毕业生。
- Marc Oczachowski joined the Company in May 1997 as Area Sales Manager, based in Lyon, France. From March 2001 to January 2004 he held management positions as General Manager of EDAP Technomed Malaysia. He was appointed Chief Operating Officer of EDAP TMS in November 2004 and became Chief Executive Officer of the Company on March 31 2007. From July 2012 to July 2017 he relocated to Austin, Texas to manage EDAP’s U.S. operations. On March 25 2020 he was appointed Chairman of the Board of Directors following Philippe Chauveau’s decision to step down from this position. Previously he worked for Sodem Systems, which manufactures orthopedic power tools, as Area Sales Manager. He is a graduate of Institut Commercial de Lyon, France.